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Abstract 
 
In the public hospital sector in Australia there is no dedicated scheme to offset 
costs associated with high cost medications (HCMs) to the institution or the public. 
(1) Concerns exist as to the equity of access and appropriate mechanisms to 
manage access to HCMs in public hospitals. (2) There are gaps in the literature as 
to how decisions are made, and in particular, decision-making processes by which 
ethical, clinical and economic considerations maybe taken into account.   
 
To date, limited work has been conducted regarding the use and funding of HCMs 
in public hospitals. There are no published data on perceptions, concerns and 
attitudes, among health care decision-makers or among the community-at-large 
about access to HCMs in public hospitals. 
 
The research reported in this thesis describes the decision-making process and 
criteria used by health care decision-makers to allocate resources to HCMs in 
public hospitals.  The investigation triangulated quantitative and qualitative methods 
used to collect and analyse data.  Four studies were conducted to describe the 
decision-making process and explore the perceptions, concerns and attitudes of 
health care decision-makers and the perceptions of members of the general public 
regarding access to HCMs in public hospitals.  
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The first study, reported in Chapter Three, was a review of individual patient use 
(IPU) requests for non-formulary HCMs. This study showed that these requests had 
a significant impact on the capped expenditure of a public hospital. Subsequent to 
this review, a new policy and procedure for managing requests for HCMs for IPU 
was established. A high-cost drugs subcommittee (HCD-SC) operating under the 
auspices of the Drug and Therapeutics Committee (DTC) was created.  
 
The second study, reported in Chapter Four, described the operations of the newly 
formed HCD-SC. This study also evaluated the decision-making process using the 
ethical framework “accountability for reasonableness”. (3) Different factors were 
involved in decisions about access to HCMs and decisions were not solely based 
on effectiveness and cost. HCD-SC members considered it was important to have 
consistency in the way decisions were being made.  The evaluation of this process 
allowed identification of good practices and gaps which were considered as 
opportunities for improvement.   
 
The third study, reported in Chapter Five, found that health care decision-makers in 
an Area Health Service echoed the concerns and agreed about the problems 
associated with access to HCMs expressed by the HCD-SC members. These 
studies concluded that the majority of decision-makers wanted an explicit, 
systematic process to allocate resources to HCMs.   
 
These studies also identified tensions between funding systems and hospital 
decision-making. According to participants there were no mechanisms in place to 
systematically capture, analyse and share the lessons learned between the macro 
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level (ie. Federal, Pharmaceutical Benefits Scheme - PBS) and the meso level (ie. 
Institution, public hospital) regarding funding for HCMs. Furthermore, decision-
makers considered there are strong incentives for cost-shifting between the 
Commonwealth and the States.  
 
Health care decision-makers also acknowledged the importance of public 
participation in decision-making regarding allocation of resources to HCMs in public 
hospitals. However the results of these studies showed that those decisions were 
not generally made in consultation with the community. Decision-makers perceived 
that the general public does not have good general knowledge about access to 
HCMs in public hospitals.   
 
A survey of members of the general public, reported in Chapter Six, was then 
conducted. The survey aimed to gather information about the knowledge and views 
of members of the general public about access to HCMs in public hospitals. Results 
of this fourth study showed that respondents had good general knowledge but were 
poorly informed about the specifics of funding of hospitals and HCMs in private and 
public hospitals. The results also offered support for the development of a process 
to involve community members in discussion on policy on the provision of treatment 
and services within health care institutions and specifically, to seek the views of 
members of the public on the provision of HCMs and expensive services within 
public hospitals. 
 
In summary, the research reported in this thesis has addressed the gaps in the 
literature as to how decisions are made, and in particular, the decision-making 
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process and criteria used by health care decision-makers to allocate resources to 
HCMs in public hospitals. In a move towards more explicitness in decision-making 
regarding the allocation of scarce health care resources, the findings from these 
studies provide an evidence base for developing strategies to improve decision-
making processes regarding access to HCMs the public sector. 
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Preface 
 
 
The studies that form part of this thesis were conducted to investigate the decision-
making process for allocation of resources to high cost medications (HCMs) in 
public hospitals in Australia. Multiple methodological approaches have been used to 
develop understanding of the perceptions, concerns and attitudes of healthcare 
decision-makers and members of the general public regarding this process.  
 
The research was undertaken using both quantitative and qualitative methods.   
Qualitative methods involved case study and grounded theory approaches.  The 
qualitative analysis followed inductive reasoning and employed ‘triangulation’ to 
describe health care decision-maker’s perceptions, concerns and attitudes 
regarding access to HCMs.  Quantitative data on perceptions of the members of the 
general public were collected using a survey instrument. 
 
The thesis is divided in three parts. Part one describes the literature and includes 
Chapters One and Two. Part two, Chapters Three and Four describes the decision-
making process to access HCMs in public hospitals. Part three explores the 
decision-making process to allocate resources to HCMs and explores the 
perceptions, concerns and attitudes of health care decision-makers and the general 
public regarding access to HCMs in public hospitals.  
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Chapter One describes the Australian health care system and mechanisms for 
access to medicines.  Chapter Two describes the literature on levels of decision-
making, priority setting in health care and the role of the general public in setting 
these priorities.  
 
Chapter Three is a retrospective study that describes the Individual Patient Use 
(IPU) scheme in a public hospital and provides a review of the impact of this 
scheme on medication expenditure.   
 
Chapter Four is a case-study that describes the operation of the first reported High 
Cost Drug Subcommittee (HCD-SC) in a public hospital in Australia.  This case 
study uses a mixture of qualitative and quantitative methodologies and offers an 
insight into how decisions are being made regarding access to HCMs in a public 
hospital.  
 
Through a qualitative research approach, Chapter Five describes the perceptions, 
concerns and attitudes of health care decision-makers regarding access to HCMs in 
public hospitals.   
 
The survey presented in Chapter Six describes the perceptions of members of the 
general public regarding access to HCMs in public hospitals. Chapter Seven draws 
conclusions and comments on implications of this work.  
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The work undertaken in this thesis increases the understanding on how decisions 
are being made in public hospitals regarding access to HCMs. It provides an 
understanding of the perceptions, concerns and attitudes of health care decision-
makers about the allocation of resources to HCMs in public hospitals.   
